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Summary
In neuroblastoma specimens, HIF-2a but not HIF-1a is strongly expressed in well-vascularized areas. In vitro, HIF-2a protein
was stabilized at 5%O2 (resembling end capillary oxygen conditions) and, in contrast to the lowHIF-1a activity at this oxygen
level, actively transcribed genes like VEGF. Under hypoxia (1%O2), HIF-1awas transiently stabilized and primarily mediated
acute responses, whereas HIF-2a protein gradually accumulated and governed prolonged hypoxic gene activation. Knock-
down of HIF-2a reduced growth of neuroblastoma tumors in athymicmice. Furthermore, highHIF-2a protein levelswere cor-
related with advanced clinical stage and high VEGF expression and predicted poor prognosis in a clinical neuroblastoma
material. Our results demonstrate the relevance of HIF-2a in neuroblastoma progression and have general tumor biological
implications.Introduction
The oxygen pressure within solid tumors is heterogeneous,
ranging from approximately 5% O2 in well-vascularized regions
to anoxia near necrotic regions, but is on average in the hypoxic
range (about 1% O2) (Brown and Wilson, 2004; Goda et al.,
1997; Ho¨ckel and Vaupel, 2001). In response to hypoxia, tumor
cells adapt by changing the transcription of genes involved in
angiogenesis, cell survival, and metabolism. The hypoxia-induc-
ible transcription factors HIF-1a and HIF-2a are critical for this
adaptive response (Harris, 2002; Semenza, 2003). At hypoxia
the a subunits are stabilized, heterodimerize with the constitu-
tively present partner HIF-1b/ARNT, and together with coactiva-
tors such as CBP/p300 regulate genes via specific hypoxia re-
sponse elements (HREs) (Semenza, 2003). In the presence of
oxygen, prolyl hydroxylases (PHDs) modify the HIF-a proteinsCANCER CELL 10, 413–423, NOVEMBER 2006 ª2006 ELSEVIER INC. Dat two conserved prolines, resulting in HIF interaction with the
von Hippel-Lindau (VHL)-E3 ligase protein complex, targeting
HIFs for ubiquitylation and subsequent proteasomal degrada-
tion (Epstein et al., 2001; Huang et al., 1998; Kallio et al.,
1999). HIF transcriptional activity is further regulated by an oxy-
gen-dependent asparagyl hydroxylase, FIH-1 (factor inhibiting
HIF) leading to reduced interaction with CBP/p300 coactivators
(Lando et al., 2002; Mahon et al., 2001). In addition to hypoxia,
HIF-1a protein synthesis, stability, and activity can also be reg-
ulated by other mechanisms, for instance, in response to growth
factor-induced signaling (Semenza, 2003).
There are several known and well-characterized HIF-1a target
genes (Semenza, 2003; Wenger et al., 2005), whereas no exclu-
sive HIF-2a target gene has yet been identified, with the possible
exception of the recently reported Oct-4 (Covello et al., 2006).
There is a redundancy regarding HIF targets (Sowter et al.,S I G N I F I C A N C E
Mechanisms for efficient cellular adjustment to oxygen shortage probably evolved in parallel to development of oxygen-dependent
multiorgan organisms. The hypoxic response through HIF transcription factors results in phenotypic changes much resembling those
of neoplastic progression. Generally, tumor hypoxia/presence of HIF-1a protein correlates with poor prognosis. The presence of
HIF-2a in well-vascularized neuroblastomas correlates with VEGF expression and unfavorable patient outcome. Moreover, the obser-
vation that HIF-2a regulates classical hypoxia-driven genes (such as VEGF) at end capillary O2 levels indicates that HIF-2a can act
oncogenically, independently of a hypoxic environment. The present data also suggest differential utilization of HIF proteins in neuro-
blastomacells at acute versus prolonged hypoxia, which could have significant implications for the design of anti-HIF therapy in tumor
disease.OI 10.1016/j.ccr.2006.08.026 413
A R T I C L E2003); however, it has been reported that these two factors
display some differences in their preference for the genes they
regulate. For example, glycolytic enzymes are suggested to be
preferentially targeted by HIF-1a (Hu et al., 2003; Wang et al.,
2005), whereas HIF-2a appears to regulate the expression of
MT1-MMP (Petrella et al., 2005), EPO (Warnecke et al., 2004),
andPAI-1 (Sato et al., 2004), although these genes are regulated
by HIF-1a as well (Semenza, 2003). HIF-1a expression is found
in most cell types (Jain et al., 1998), and hif-1a2/2 mice die at
approximately embryonal day 11 (E11) with neural tube defects
and cardiovascular malformations, reflecting the importance of
HIF-1a during development (Iyer et al., 1998; Ryan et al., 1998).
HIF-2a is highly expressed in vascular structures (Jain et al.,
1998) but also in distinct cell populations of most organs, includ-
ing brain, heart, lung, kidney, and liver (Wiesener et al., 2003).
During embryogenesis, HIF-2a protein is selectively expressed
during short, discrete time periods in different parts of the devel-
oping murine and human sympathetic nervous system (SNS)
(Jo¨gi et al., 2002; Nilsson et al., 2005; Tian et al., 1998), and
a role in normal SNS development has been proposed (Tian
et al., 1998). In hif-2a2/2 mice, reduced catecholamine synthe-
sis (Tian et al., 1998) and severe vascular defects (Peng et al.,
2000) have been demonstrated. HIF-1a and HIF-2a have also
been implicated in tumorigenesis (Harris, 2002; Semenza,
2003) and are frequently coexpressed in human tumors (Talks
et al., 2000).
The childhood tumor neuroblastoma is derived from SNS pre-
cursor cells or immature SNS neuroblasts (Hoehner et al., 1996).
We have previously shown that neuroblastoma cells respond to
low oxygen by induction of a hypoxic phenotype and that hyp-
oxic neuroblastoma cells become dedifferentiated and gain
SNS stem cell characteristics (Jo¨gi et al., 2002, 2004), features
that in the clinical setting are associated with increased aggres-
siveness and adverse patient outcome (Wei et al., 2004). Here
we report that neuroblastoma specimens frequently have strong
expression of HIF-2a protein in well-vascularized tumor areas.
In vitro, HIF-2a, as opposed to HIF-1a protein, is strongly
induced at physiological oxygen concentrations (5% O2). Fur-
thermore, under chronic hypoxia (1% O2) HIF-1a protein is de-
graded over time, whereas HIF-2a is continuously accumulated.
Global gene expression analysis revealed genes closely follow-
ing the HIF stabilization patterns at 1% and 5% O2. HIF subcel-
lular localization and genomic DNA binding, together with spe-
cific HIF knockdown, indicated a temporally regulated mode
of HIF utilization during cellular adaptation to hypoxia, where
HIF-1a primarily mediates fast (acute) and HIF-2a mediates
late (chronic) responses to hypoxia. In addition, expression of
known hypoxia-driven genes were induced in a HIF-2a-depen-
dent manner at 5% O2, indicating a role of HIF-2a in promotion
of an aggressive neuroblastoma phenotype at physiological as
well as chronic hypoxic oxygen levels. Accordingly, transient
knockdown of HIF-2a reduced growth of xenografted neuro-
blastoma tumors in athymic mice. Immunohistochemical evalu-
ation of a clinical neuroblastoma tumor material further demon-
strated a significant correlation between HIF-2a and VEGF
protein levels, and a strong and significant correlation between
high HIF-2a protein content and unfavorable patient outcome
was found. Taken together, these data clearly implicate
HIF-2a as an important factor determining neuroblastoma
aggressiveness, and HIF-2a could therefore represent an im-
portant target in neuroblastoma therapy.414Results
HIF-1a and HIF-2a induction patterns
differ in neuroblastoma cells
We immunostained consecutive sections of neuroblastoma
specimens for HIF proteins and the blood vessel endothelial
marker CD31. We consistently (18/20 tumors) found weak to
strong HIF-2a immunoreactivity in tumor cells adjacent to blood
vessels (Figures 1A–1B), while HIF-1a staining in vascularized
areas was negative (data not shown). Importantly, the HIF-2a
protein was frequently localized to nuclei, consistent with func-
tional activity also in well-vascularized lesions. These observa-
tions prompted us to analyze in closer detail the kinetics by
which HIF protein levels and functions change in cultured neuro-
blastoma cells at different oxygen levels. At 1% O2, HIF-1a
levels were rapidly induced to peak within hours and thereafter
gradually declined to low levels at 72 hr in both SK-N-BE(2)c and
KCN-69n neuroblastoma cell lines (Figures 1C and 1D). Analysis
of HIF-2a protein levels at 1% O2 revealed an almost opposite
pattern. After an initial induction at 2 hr of hypoxia, HIF-2a pro-
tein levels increased over time and were upregulated after 72 hr
in both analyzed neuroblastoma cell lines (Figures 1C and 1D).
To mimic more physiological growth conditions with an oxygen
pressure closer to that present in end capillaries, i.e., around 5%
O2 (Goda et al., 1997), we exposed neuroblastoma cells to 5%
O2 and analyzed HIF protein levels (Figures 1E and 1F). Whereas
basal or induced HIF-1aprotein was hardly detectable, a gradual
and prominent increase over time in HIF-2a protein levels was
seen in both cell lines, in agreement with the in vivo situation
with high HIF-2a levels in well-oxygenated tumor areas. The
steady-state levels of HIF-1a mRNA remained virtually unaf-
fected (Figures 1G and 1H), while HIF-2a mRNA levels were up-
regulated at 1% and 5% O2 in both cell lines (Figures 1I and 1J).
The differential changes over time of the HIF proteins at 1% O2
and the seemingly efficient degradation of HIF-1a at 5% O2
might reflect the expression levels of HIF-regulating PHDs under
these conditions. In SK-N-BE(2)c (Figures 2A–2C) and KCN-69n
(data not shown) cells, no consistent induction or reduction of
PHD1 mRNA levels was seen at either 21%, 5%, or 1% O2. In
contrast, as expected (Marxsen et al., 2004), a robust increase
in PHD2 and PHD3 mRNA at both 5% and 1% O2 was observed
in both tested cell lines. PHD2 protein levels were induced at 1%
O2 in both tested cell lines, whereas no or limited induction was
seen at 5% O2 (Figures 2D–2G). Thus, despite the raise in PHD2
and PHD3 expression with time, HIF-2a protein increased at
both 5% and 1% O2, suggesting that HIF-2a is less sensitive to
PHD2- and PHD3-induced degradation than HIF-1a is in neuro-
blastoma cells. Alternatively, as HIF-2a mRNA levels increase
at 5% and 1% O2, high de novo HIF-2a protein synthesis might
counteract an increased PHD-induced degradation. Both HIF
proteins were rapidly stabilized by the PHD inhibitors CoCl2
and DIP (Figure S1). After 24 hr, HIF-1a protein was still present
in cultures containing inhibitors, while HIF-2a protein in CoCl2-
treated cells decreased after 24 hr, in contrast to the sustained
HIF-2a levels observed in DIP-treated and hypoxic cells (Fig-
ures S1A and S1B). As the HIF-2a mRNA levels increased in
DIP- and CoCl2-treated cells, but to a lesser extent in CoCl2-
treated cells (Figures S1C–S1F), it is possible that the high
and sustained HIF-2a protein levels at hypoxia reflect the com-
bined result of increased protein synthesis and less efficient
protein degradation.CANCER CELL NOVEMBER 2006
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in neuroblastoma cells at 1% and 5% O2
To evaluate the functional activity of HIF proteins at hypoxia and
physiological oxygen tensions, we initially assessed their sub-
cellular localization at 21%, 5%, or 1% O2 in SK-N-BE(2)c cells.
HIF-2a protein present at 21% O2 was mainly detected in cyto-
solic extracts. At 5% O2, induced HIF-2a was initially mainly
Figure 1. HIF-2a protein is present in well-vascularized neuroblastomas and
in neuroblastoma cells cultured at physiological oxygen tensions
A and B: Immunohistochemical detection of nuclear HIF-2a (arrows, A) in
well-vascularized areas of a stage 4 neuroblastoma specimen. CD31-posi-
tive vascular endothelial cells (arrowheads) are shown in a consecutive sec-
tion (B). Scale bars, 100 mm.
C–J: HIF-1a and HIF-2a expression in neuroblastoma cells. C–F: Western blot
analyses of changes in HIF-1a and HIF-2a protein levels in SK-N-BE(2)c and
KCN-69n cells grown at either 1% (C and D) or 5% (E and F) O2 for 0–72 hr.
For comparison, HIF levels in cells grown at 21% O2 are shown, and HIF-1a
and HIF-2a in vitro translated (iv) proteins were used as positive controls. Rep-
resentative results of three independent experiments are shown. G–J: Rela-
tive amounts of HIF-1a (G and H) and HIF-2a (I and J) mRNA, in SK-N-BE(2)c
(Gand I) and KCN-69n (Hand J) cells as detected by Q-PCR.HIF-1aandHIF-
2a mRNA levels are correlated to the expression of three reference genes
(SDHA, YWHAZ, and UBC). Error bars denote the standard deviation within
triplicates.CANCER CELL NOVEMBER 2006cytoplasmic, but after 72 hr most protein was accumulated in
the nucleus (Figures 3A and 3B). As expected, no or small
amounts of HIF-1a protein was detected at 21% or 5% O2. In
contrast, massive stabilization and nuclear localization of both
HIF-1a and HIF-2a proteins were seen at 1% O2 (Figures 3A
and 3B). After 72 hr of growth, the small amount of HIF-1a pro-
tein detectable at 1% O2 appeared to be nuclear.
HIF protein data at prolonged hypoxia and at 5% O2 (Figures 1
and 3), and the fact that hypoxia-driven genes like VEGF and
DEC1/BHLHB2 are still expressed during chronic hypoxia
(Jo¨gi et al., 2002; Miyazaki et al., 2002), suggest that HIF-2a
rather than HIF-1a is the major transcriptional regulator of pro-
longed hypoxic responses and that HIF-2a is active at physio-
logical oxygen levels. The capacities of HIF-1a and HIF-2a to
bind the HREs of the VEGF and DEC1/BHLHB2 promoters at
these conditions were tested by chromatin immunoprecipitation
(ChIP) assays. The most robust binding of HIF-1a to the VEGF-
HRE was detected after 4 hr at 1% O2, whereas interaction with
HIF-2a was most pronounced after 24 hr at 5% O2 (Figure 3C).
Figure 2. Kinetics of PHD mRNA and protein in neuroblastoma cells grown
for 72 hr at 21%, 5%, or 1% O2
A–C: Relative amounts of PHD1, PHD2, and PHD3 mRNA in SK-N-BE(2)c cells
were determined by Q-PCR and related to the mRNA levels of three refer-
ence genes (SDHA, YWHAZ, and UBC). Error bars show the standard devia-
tion within triplicates.
D–G: PHD2 protein in SK-N-BE(2)c and KCN-69n cells cultured at 1% (D and E)
and 5% (F and G) O2. PHD2 levels at 21% O2 are shown for comparison, and
actin was used as a loading control. Data represent three independent ex-
periments.415
A R T I C L EFigure 3. Subcellular localization and functional
activity of HIF-1a and HIF-2a proteins in neuro-
blastoma cells
A and B: Whole-cell lysates (whole) and nuclei-
enriched (nuc) and cytoplasmic (cyt) fractions
of SK-N-BE(2)c cells were analyzed by immuno-
blotting. For relevant comparison, 60 mg of
whole-cell protein lysates and the correspond-
ing percentage of nuclear and cytoplasmic
fractions were used for analysis. GAPDH and
lamin B served as cytoplasmic and nuclear
markers, respectively. Representative results of
three independent experiments.
C and D: HIF-1a and HIF-2a binding to the VEGF
and DEC1/BHLHB2 promoters. ChIP assays on
SK-N-BE(2)c cells exposed to 21%, 5%, or 1% O2
for 4 and 24 hr. DNA was immunoprecipitated
with anti-IgG control, anti-HIF-1a, or anti-HIF-2a
antibodies, respectively. DNA was amplified by
PCR, using primers flanking the VEGF-HRE and
DEC1/BHLHB2-HRE, which generated amplicons
of 275 and 166 bp, respectively. For input control,
DNA from nonimmunoprecipitated extracts was
used.
E: HRE transcriptional activity in neuroblastoma
cells at 1% and 5% oxygen. SK-N-BE(2)c cells
were transfected with a vector containing three
copies of the EPO-HRE coupled to a Luciferase
reporter gene. For reference, cells were cotrans-
fected with a CMV Renilla Luciferase vector.
Cells were cultured at 21, 5%, and 1% O2 for 24
hr followed by measurements of Luciferase ac-
tivity. Ratios between HRE and Renilla luciferase
activities (HRE/CMV) were calculated and nor-
malized to the control samples (21% O2) in
each experiment. Error bars show standard devi-
ation of triplicate experiments.Weak HIF-2a precipitates were also obtained at 4 hr at both 1%
and 5% O2. Binding of HIF-1a to the VEGF promoter could be
detected in cells grown at 5% O2 but was substantially reduced
as compared to binding at 4 hr 1% O2. A similar HIF-binding
pattern was seen when analyzing occupancy of the DEC1/
BHLHB2-HRE. Notably, HIF-2a binding was detected primarily
at 24 hr (Figure 3D). In addition, neuroblastoma cells grown at
5% O2 have the capacity to transcribe genes via HIF-binding
HREs, as demonstrated in cells transfected with a vector con-
taining three copies of the EPO-HRE coupled to a luciferase re-
porter gene (Figure 3E).
Gene induction at 1% and 5% oxygen correlates
with differential regulation of HIF-a stability
As demonstrated previously (Jo¨gi et al., 2002), and supported by
data presented here, the overall response and adaptation to
hypoxia are similar among neuroblastoma cell lines. A represen-
tative cell line for this response is SK-N-BE(2)c, and mRNA from
these cells grown at 1%, 5%, and 21% O2 for 0–72 hr was ana-
lyzed using microarray assays. Microarray expression data of
tyrosine hydroxylase (TH) showed correlation to the HIF-1a
and HIF-2a protein level patterns with regard to the rapid induc-
tion at 1% and the delayed upregulation at 5% O2 (Figure 4A).
These observations were independently validated using Q-PCR
(Figure 4B). The TH expression pattern, representing an interest-
ing data structure regardless of factual HIF dependence, was
used as a template for further microarray data analyses. Genes
with a similar microarray expression pattern were identified by416calculating the projection length for each gene vector in the
1% O2 series (n = 12,407; genes with valid expression data
for all seven time points) onto the TH log2 expression vector
(TH 1% O2) (Figure S2A). Low absolute-valued projection
lengths, centering on zero, were found to show no specific cor-
relation to the TH vector. High projection lengths correlated well
to the expression pattern of TH 1% O2, whereas the most ex-
treme negative projection lengths were anticorrelated to TH
1% O2. By permuting the sample labels 1000 times and assay-
ing projection length distribution in comparison to that of the ob-
served data, a statistically significant projection length cut-off
level was defined (Figure S2B). Genes having a projection length
larger than 4.1 (p = 0.040) were considered significantly in-
duced. These calculations gave a data set of 75 array reporters
representing 64 known genes and five ESTs (Figure 5) with an
expression pattern at 1% O2 highly resembling that of TH (cf.
Figures 4 and 5). Several of the identified genes have been dem-
onstrated to be hypoxia responsive (Hu et al., 2003; Jo¨gi et al.,
2004; Semenza, 2003; Wenger et al., 2005). Using the TFASTA
sequence comparison program, two ESTs were identified as
the human endogenous retroviral genes ERV3 (ENR1_HUMAN,
E = 1.1 3 10252) and ENT1 (ENT1_HUMAN, E = 3.2 3 10274).
Some of the 64 genes have previously not been highlighted as
being hypoxia driven, including TRIO and SERPINB9, both
highly implicated in tumorigenesis and cell survival (van Houdt
et al., 2005; Zheng et al., 2004). The early and sustained TH pat-
tern seen at 1% O2 was not significant for any group of genes at
5% or 21% O2 (data not shown), but instead several of the 75CANCER CELL NOVEMBER 2006
A R T I C L Eidentified array reporters showed over time a slow increase in
expression at 5% O2 (Figure 5). Principal component analysis
on the log2 ratio values followed by one-way ANOVA (p <
0.001) and Bonferroni-corrected pairwise Student’s t tests (p <
0.001) between the oxygen treatment groups revealed that
this was a general pattern among the 75 array reporters (Fig-
ure 4C). In summary, we demonstrate a strong, rapid, and signif-
icant induction of the identified genes at 1% O2. In contrast, no
significant induction was observed at 21% O2. However, a slow
induction was detected at 5% O2, very similar to that docu-
mented for TH (cf. Figures 4 and 5). We confirmed this general
expression pattern for a set of the 64 genes in two
Figure 4. TH as a model gene for hypoxia-driven expression mimicking the
stabilization patterns of HIF-1a and HIF-2a in neuroblastoma cells
A: TH mRNA levels in SK-N-BE(2)c cells grown at 1%, 5%, or 21% O2 at indi-
cated time points, as monitored by 70-mer oligonucleotide microarrays.
B: TH expression at corresponding oxygen levels and time points verified by
Q-PCR, as related to the expression of three reference genes (SDHA,
YWHAZ, and UBC).
C: Separation, using principal component analysis, of the 75 significantly in-
duced genes, grouped by the three different oxygen levels. The median for
each data set is indicated by the thick center line, and the first and third
quartiles are the edges of the box. The brackets of the dashed vertical lines
extending from the box show the last nonoutlier values, and points plotted
individually represent potential outliers. The first principal component shown
here described 83.2% of the variance in the data set. Groups were signifi-
cantly different as determined by one-way ANOVA (p < 0.001) and Bonfer-
roni-corrected pairwise Student’s t tests (p < 0.001).CANCER CELL NOVEMBER 2006neuroblastoma cell lines using Q-PCR as exemplified by
DEC1/BHLHB2 and NDRG1 (Figures 6A–6D).
HIF target genes differentially utilize HIF proteins
at acute and prolonged hypoxia and at 5% O2
To distinguish between HIF-1a- and HIF-2a-driven transcrip-
tion, small inhibitory RNAs (siRNAs) against HIF-1a and HIF-2a
were employed, focusing on the transcriptional activity of genes
identified in our microarray analysis (Figure 5). We first con-
firmed a specific reduction of HIF mRNA and protein by cognate
siRNA treatment at 4 and 24 hr at 1% O2, and at 5% O2 for 24 hr
(Figures 7A, 7B, 7G, and 7H and Figure S3A). Upon acute (4 hr)
hypoxic treatment, induced expression of VEGF and DEC1/
BHLHB2 was downregulated by siRNA against HIF-1a but not
HIF-2a (Figures 7C and 7E). However, at prolonged hypoxia
(1% O2 for 24 hr) HIF-2a siRNA, in addition to HIF-1a siRNA,
substantially reduced VEGF and DEC1/BHLHB2 mRNA levels
(Figures 7D and 7F). Taken together, our results strongly sug-
gest that HIF-1a and HIF-2a act on the same genes but during
different temporal windows, with HIF-1a primarily activated at
the acute hypoxic phase and HIF-2a at later, prolonged stages
of cellular adaptation to hypoxia.
The protein stabilization and subcellular localization data
shown in Figures 1 and 3 in combination with the microarray
analysis suggested that HIF-2a could be the dominant active
HIF at 5% O2. To directly test this notion, the expression levels
of five selected genes identified in the microarray, TH, VEGF,
DEC1/BHLHB2, NDRG1, and SERPINB9, were investigated in
cells grown at 5% O2 in the absence or presence of siRNA
against either HIF-1a or HIF-2a. As shown in Figures 7I–7M,
the expression of these genes was substantially reduced by
HIF-2a siRNA. HIF-1a siRNA also reduced TH, DEC1/BHLHB2,
and NDRG1 expression, albeit with lower efficiency than siRNA
against HIF-2a. Interestingly, VEGF and SERPINB9 mRNA
levels were virtually unaffected by HIF-1a siRNA at 5% O2 but
were clearly reduced by HIF-2a knockdown (Figures 7J and
7M). These results demonstrate that HIF-2a is actively regulat-
ing hypoxia-driven genes at physiological oxygen tensions.
We also found that knockdown of either HIF-1a or HIF-2a re-
duced the mRNA levels of the glycolytic enzyme PGK1, indicat-
ing that HIF-2a can affect putative HIF-1a-specific target genes
at physiological oxygen levels, at least in neuroblastoma cells
(Figure 7N). However, not all genes induced at 5% O2 appeared
to be primarily regulated by HIF-2a, as exemplified by BNIP3
(Figure 7O).
HIF-2a promotes an aggressive neuroblastoma
phenotype
The specific effect of HIF-2a siRNA treatment on VEGF expres-
sion at 5% O2, the known proangiogenic activity of VEGF, and
the demonstrated correlation between blood vessel density
and aggressiveness in many tumor forms (Carmeliet, 2005)
prompted us to investigate if HIF-2a and VEGF were coex-
pressed in neuroblastoma specimens and whether HIF-2a pro-
tein is associated with an unfavorable outcome. Neuroblastoma
specimens were immunohistochemically stained with anti-
VEGF antibodies and screened for colocalization of VEGF and
HIF-2a immunoreactivity in well-vascularized tumor areas, as
defined by the presence of CD31-positive vascular endothelial
cells. As illustrated in Figures 8A–8C, a strikingly concordant
pattern of localized HIF-2a, VEGF, and CD31 immunoreactivity417
A R T I C L EFigure 5. mRNA expression patterns for 75 signifi-
cantly hypoxia-induced genes shown at 1% and
5% O2
Genes were identified as hypoxia induced at 1%
O2 by calculation of projection length onto the
target gene TH. Ranks are based on magnitude
of calculated projection lengths in decreasing
order. Entrez GeneID and Gene Symbol refer to
the Entrez Gene database (Entrez Gene, http://
www.ncbi.nih.gov/entrez/query.fcgi?db=gene).
Genes with symbols in italics were identified using
TFASTA and refer to Swiss-Prot (ExPASy-Swiss-Prot
and TrEMBL, http://www.expasy.org/sprot/).
Symbols for unidentified genes (starting with
‘‘H .’’) refer to the Oligo MicroArray Database
(Operon) (Oligo MicroArray Database, OMAD,
http://www.operon.com/arrays/omad.php?/).
Genes are grouped for presentation purposes
only.was frequently observed. These data suggest that HIF-2a may
drive the expression of VEGF and, hence, angiogenesis and
tumor growth. To assess the importance of HIF-2a on tumor
growth in vivo, neuroblastoma cells transiently transfected
with siRNA against HIF-2a were injected into athymic mice.
The time for tumor take did not significantly differ between the
HIF-2a siRNA (4.3 6 1.4 days) and control siRNA (4.6 6 1.2
days) groups. However, strikingly, tumor growth was signifi-
cantly impaired by targeting HIF-2a (Figure 8D). In contrast,
transient knockdown of HIF-1a did not significantly affect xeno-
graft tumor growth (Figure S3B).418To further investigate the in vivo effects of HIF-2a protein ex-
pression, we analyzed 93 primary neuroblastoma tumors ar-
ranged in a tissue microarray, addressing the hypothesis of local
coexpression of HIF-2a and VEGF (cf. Figures 8A and 8B). We
also analyzed whether HIF-2a levels could provide prognostic
information regarding disease outcome. Tissue microarray sec-
tions, immunohistochemically stained for HIF-2a and VEGF,
were scored as fractions of positive cells (range) as well as ac-
cording to general intensity of positive cells. HIF-2a and VEGF
correlated positively irrespective of whether range (p < 0.001)
or intensity (p = 0.009) was used as the immunoreactivityCANCER CELL NOVEMBER 2006
A R T I C L Emeasure (exemplified in Figure 8E). In addition, high HIF-2a in-
tensity correlated significantly to high clinical stage (p =
0.028). To evaluate the prognostic significance of HIF-2a protein
levels, Kaplan-Meier survival analysis was performed. A clear
and significant difference in survival (p = 0.004) was seen, with
high HIF-2a intensity predicting low overall survival (Figure 8F).
A similar analysis for VEGF did not demonstrate a significant
correlation to survival (data not shown), suggesting that HIF-
2a affects tumor aggressiveness beyond the induction of
VEGF expression. A further analysis of only the high-stage tu-
mors (stages 3 and 4) revealed that HIF-2a intensity predicted
survival also in this material (p = 0.043) (Figure 8G), making
HIF-2a a prognostic marker independent of the clinical staging
according to INSS (International Neuroblastoma Staging Sys-
tem). In conclusion, high levels of HIF-2a are associated with
worse overall prognosis, and our results suggest that VEGF
might be one of the downstream effectors contributing to this
aggressive phenotype.
Discussion
HIF-1a has been directly or indirectly linked to the regulation of
most investigated hypoxia-induced genes. The corresponding
role of HIF-2a, on the other hand, is less clear (Park et al.,
2003; Poellinger and Johnson, 2004; Takahashi et al., 2004).
Gene elimination data indicate that HIF-2a function is required
during development (Peng et al., 2000; Tian et al., 1998). In can-
cer, the HIF proteins are frequently coexpressed, thereby raising
the questions of what their specific roles in growth and develop-
ment of tumors are, and which genes are regulated by HIF-1a
and by HIF-2a, respectively. Based on our data and the reported
substantial redundancies in the utilization of the HIFs (Raval
et al., 2005; Sowter et al., 2003; Warnecke et al., 2004), we argue
that the answer lies not in which genes are transcribed by HIF-1a
or HIF-2a, but rather in the conditions under which HIF-1a and
Figure 6. Verification by Q-PCR of the expression of two selected genes,
which were identified by the microarray analysis and are correlated with
the HIF stabilization and activity patterns at 1% and 5% oxygen
Expression levels of DEC1/BHLHB2 (A and B) and NDRG1 (C and D) were an-
alyzed in SK-N-BE(2)c (A and C) and KCN-69n (B and D) cells grown at 21%,
5%, and 1% O2 and related to the mRNA levels of three reference genes
(SDHA, YWHAZ, and UBC).CANCER CELL NOVEMBER 2006HIF-2a are stabilized, transcriptionally active, and subsequently
utilized by hypoxia-regulated genes. We suggest that there is
a temporal shift in HIF utilization, where HIF-1a is primarily active
during the acute phase of hypoxic adaptation, and HIF-2a dom-
inates during later, more chronic phases of hypoxia (Figure 8H).
In addition, our data demonstrate that HIF-2a is also active at
end capillary oxygen tensions, i.e., around 5% O2. The finding
that a number of classic hypoxia-driven genes can be tran-
scribed by either HIF depending on the growth conditions might
Figure 7. Differential utilization of HIF proteins in neuroblastoma cells de-
pending on duration and severity of oxygen deprivation
Effects of selective siRNA treatment against HIF-1a and HIF-2a, respectively.
SK-N-BE(2)c neuroblastoma cells were transfected at 21% O2, and 16 hr after
transfection, cultures were shifted to growth at 1% (A–F) or 5% (G–O) O2. HIF
mRNA expression (A and B) and expression of the known hypoxia-driven
genes VEGF (C and D) and DEC1/BHLHB2 (E and F), also identified in our mi-
croarray analysis, were analyzed at acute (4 hr) and prolonged (24 hr) hyp-
oxia. G–O: HIF-2a regulates hypoxia-driven genes at physiological oxygen
tensions in neuroblastoma cells. Expression of HIF-1a (G), HIF-2a (H), TH (I),
VEGF (J), DEC1/BHLHB2 (K), NDRG1 (L), SERPINB9 (M), PGK1 (N), and BNIP3
(O) was investigated in cells grown at 5% O2 for 24 hr with or without siRNA
against HIF-1a and HIF-2a, respectively. All mRNA levels were determined
by Q-PCR analyses, and data were normalized to the expression of three ref-
erence genes (SDHA, YWHAZ, and UBC). An unspecific siRNA was used as
control. Gene expression levels at 21% oxygen are shown for comparison. Er-
ror bars show the standard deviation within triplicates.419
A R T I C L Eexplain some diverging published data, as the differential tem-
poral usage and oxygen sensitivity of the HIFs, so far, appear
to have been largely overlooked.
Figure 8. HIF-2a promotes an aggressive neuroblastoma phenotype
A–C: Immunohistochemical localization of HIF-2a (A), VEGF (B), and CD31
(C) in a stage 4 neuroblastoma tumor. Areas marked with asterisks are
shown as insets in the respective panels, and the asterisks indicate the
same position in the three consecutive sections. In C, arrows indicate blood
vessels. Scale bars, 500 mm; scale bars in insets, 100 mm.
D: Reduced tumor growth in vivo by siRNA against HIF-2a. Xenograft exper-
iment showing growth of SK-N-BE(2)c neuroblastoma cells, transfected with
siRNA targeting HIF-2a (n = 15) or control (n = 15) in athymic mice. Tumor for-
mation and volume were examined daily, and statistical significance was
determined by Student’s t test (p < 0.05). Error bars indicate SEM.
E: HIF-2a and VEGF immunoreactivities, assayed on a neuroblastoma tissue
microarray, correlate positively as described by fraction of positive cells (p <
0.001, n = 81, Spearman correlation).
F:HIF-2aprotein content predicts overall neuroblastoma patient survival (p =
0.004, n = 72, log rank test). HIF-2a intensity was scored in a four-grade scale
on a tissue microarray, and scores were pooled into two groups: low (none
and mild) and high (moderate and high) immunoreactivity.
G: HIF-2a protein content predicts survival of patients with high-stage (INSS
stages 3 and 4) neuroblastoma (p = 0.043, n = 45, log rank test). HIF-2a inten-
sity was scored as in F.
H: HIF-1a primarily governs acute hypoxic responses, whereas HIF-2a regu-
lates gene expression under physiological oxygen conditions and at pro-
longed hypoxia. Model showing protein levels and activity of HIF-1a and
HIF-2a at hypoxia (1% O2) and HIF-2a under conditions close to end capillary
oxygen levels (5% O2) in neuroblastoma cells.420As presented here, HIF-2a, in contrast to HIF-1a protein, is
highly expressed in well-vascularized and apparently nonhy-
poxic lesions of the SNS-derived tumor neuroblastoma. These
observations were corroborated by in vitro data showing that
HIF-2a is stabilized and localized in the nucleus at physiological
growth conditions (5% O2) as well as at prolonged hypoxia (1%
O2). HIF-1a levels, on the other hand, were low at 5% O2, espe-
cially in comparison to the levels at 1% O2. Microarray data, to-
gether with the demonstrated binding of HIF-2a to the VEGF and
DEC1/BHLHB2 HREs in vivo and the selective downregulation
of VEGF expression and other genes at 5% O2 by HIF-2a siRNA,
directly and unequivocally showed that HIF-2a is highly involved
in regulation of classic hypoxia-driven genes at physiological
oxygen tensions. One of these genes, NDRG1, is a known
HIF-1a target but is induced at prolonged hypoxia in HIF-1a-
negative cells (Cangul, 2004), supporting our hypothesis that
HIF-2a governs gene regulation at chronic hypoxia. The expres-
sion of some of the investigated genes was also reduced by HIF-
1a siRNA, showing that also HIF-1a can be active at physiolog-
ical oxygen tensions, but interestingly, the induction of VEGF
was seemingly unaffected by siRNA against HIF-1a at 5% O2.
The finding that PGK1 expression is slightly regulated by HIF-
2a at 5% oxygen is interesting, as PGK1 has been shown to
be a HIF-1a-driven gene in many cell systems (Covello et al.,
2005; Dayan et al., 2006; Hu et al., 2003; Wang et al., 2005).
Our results suggest that there are important differences in HIF
usage between different cell types, although there are few stud-
ies that address the HIFs at near-physiological oxygen tensions.
In support of our methodological approach, several of the genes
identified by our time course microarray analysis have functional
HREs (Semenza, 2003; Wenger et al., 2005) and showed slow
upregulation at 5% O2, establishing a general pattern as com-
pared to the 1% and 21% O2 series (Figure 4C). Among the
genes showing this mode of regulation were DEC1/BHLHB2,
NDRG1, STC1, and VEGF, all known to be induced by hypoxia
and implicated in tumorigenic processes (Chakrabarti et al.,
2004; Ryan et al., 1998; Wang et al., 2004; Yeung et al., 2005).
In this group, we also identified several genes that have previ-
ously not been described as hypoxia responsive. Of significant
interest were TRIO and SERPINB9. Amplification of TRIO in
bladder neoplasms is associated with invasive and rapid
growth, and when overexpressed in fetal kidney cells, TRIO in-
creases tumorigenicity and invasiveness (Yoshizuka et al.,
2004; Zheng et al., 2004). Overexpression of SERPINB9 is asso-
ciated with metastatic melanoma, and expression of this gene
predicts poor prognosis in anaplastic large cell lymphoma (ten
Berge et al., 2002; van Houdt et al., 2005). SERPINB9 was
also validated in our study as a HIF-2a-regulated gene at 5% ox-
ygen. The human endogenous retroviral ERV3 protein has un-
known functions but is normally expressed in the developing
SNS (Andersson et al., 2002), adding to the list of hypoxia-reg-
ulated genes that support our previous finding that hypoxia
drives neuroblastoma cells toward a neural crest-like stem cell
phenotype (Jo¨gi et al., 2002).
Hypoxia and activation of HIF-1a correlate with tumor pro-
gression and poor prognosis in several different cancers (Se-
menza, 2003). We show here that HIF-1a-driven genes can
also be transcribed by HIF-2a at 5% O2, suggesting that HIF-
2a in neuroblastoma has the potential to act oncogenically at
physiological oxygen levels as well as at prolonged hypoxia.
Published data indicate that HIF-2a could exert the effects ofCANCER CELL NOVEMBER 2006
A R T I C L Ean oncogene (Covello et al., 2005; Kondo et al., 2003; Raval
et al., 2005). However, HIF-2a, and HIF-1a as well, has been
claimed to function as a tumor suppressor protein in glioblas-
toma and teratoma models (Acker et al., 2005). In that report
and in agreement with our findings, overexpression of HIF-2a
leads to increased VEGF expression and vascularization. In dis-
agreement with our findings and the above-mentioned pub-
lished data, the net effect of HIF-2a (and HIF-1a) overexpression
on xenograft tumor growth was negative, presumably due to
HIF-induced apoptosis. Apparently there are tissue-specific dif-
ferences in response to high HIF protein levels (Blancher et al.,
2000), although the Acker et al. data await confirmation in, for
example, a larger and clinically characterized glioblastoma ma-
terial, especially since VEGF and HIF-1a expression have been
positively correlated to glioma progression (Jensen, 2006). In
summary, HIF-2a activation is undoubtedly correlated with
high tumor vascularization, and a role of HIF-2a in embryonal
vascularization has been suggested (Peng et al., 2000). Here
we show that preferentially HIF-2a and not HIF-1a mediates
transcriptional activation of VEGF at physiological oxygen ten-
sions. Accordingly, in a clinical neuroblastoma material there
was a significant correlation between high VEGF and HIF-2a
protein levels. Thus, there are strong implications for a direct in-
volvement of HIF-2a in neuroblastoma angiogenesis, and our
data suggest that this process could occur independently of
pronounced hypoxia.
By knocking down HIF-2a in cultured neuroblastoma cells
and subsequently injecting them subcutaneously in athymic
mice, early growth of the resulting tumors was reduced, demon-
strating an important role of HIF-2a in neuroblastoma growth.
This result and the finding that high HIF-2a protein levels
strongly predict adverse outcome in clinical neuroblastoma ma-
terial provide compelling support for the involvement of HIF-2a
in determining an aggressive neuroblastoma behavior. Impor-
tantly, our data also suggest that scoring HIF-2a protein levels
in high-stage neuroblastomas will give direct prognostic infor-
mation beyond that obtained by clinical staging. In addition,
we show that HIF-2a can drive expression of genes involved
in tumor migration and invasion, such as SERPINB9. In the clin-
ical setting, this could lead to HIF-2a-dependent development
of highly aggressive tumor cells also in less hypoxic tumor
areas, contributing to the phenotypical heterogeneity frequently
seen in neuroblastoma and in other solid tumors. Differences in
the kinetics by which HIF-1a and HIF-2a proteins become accu-
mulated at hypoxia have also been observed in HeLa, lung
epithelial, and breast carcinoma cells (Holmquist et al., 2005;
Uchida et al., 2004; Wiesener et al., 1998), suggesting that the
HIF accumulation patterns seen here and a putative oncogenic
role of HIF-2a are not unique to neuroblastomas. Taken to-
gether, we present evidence in support of a role of HIF-2a in
neuroblastoma angiogenesis and growth, also under nonhy-
poxic conditions. The demonstration of differential HIF utiliza-
tion under acute versus prolonged hypoxia further suggests
that any HIF-related therapeutic strategies may benefit from
selectively targeting either HIF-1a or HIF-2a.
Experimental procedures
Cell culture, western blot analysis, and quantitative real-time PCR
The SK-N-BE(2)c and KCN-69n human neuroblastoma cells were grown at
reduced oxygen levels as described (Holmquist et al., 2005). For inhibitionCANCER CELL NOVEMBER 2006of PHD activity, cells were treated with 100 mM cobalt chloride (CoCl2) or
200 mM 2,20-dipyridyl (DIP). Western blotting and cellular fractionation were
performed as described (Nilsson et al., 2005). Primary antibodies were as fol-
lows: anti-actin mAb (ICN Biomedicals), anti-HIF-1a and HIF-2amAb (Novus
Biologicals), anti-GAPDH mAb (Chemicon), anti-lamin B goat antiserum
(Santa Cruz), and anti-PHD2 Ab (Novus). Horseradish peroxidase-conju-
gated secondary antibodies and Super Signal substrate (Pierce) were used
for chemiluminescence detection.
RNA extraction, cDNA synthesis, and Q-PCR reactions with SYBR Green
PCR master mix (Applied Biosystems) were performed as described (Lo¨f-
stedt et al., 2004). Expression levels of genes of interest were normalized
to the expression of three housekeeping genes (SDHA, YWHAZ, and UBC)
not affected by reduced oxygen. Primers were designed using Primer Ex-
press (Applied), and sequences are given in Table S1.
Patient material and immunohistochemistry
Routinely fixed paraffin-embedded human neuroblastoma specimens (ethi-
cal approval LU 389-98, Lund University, Sweden) were analyzed by HIF-
1a and HIF-2a immunohistochemistry. After antigen retrieval, HIF-2a (No-
vus), VEGF (Santa Cruz), and CD31 (Dako) immunoreactivities were detected
using the Envision system and DAKO Techmate 500. A second neuroblas-
toma material consisting of 93 individual cases, selected based on tissue
quality and availability, from patients diagnosed in Spain between 1998
and 2004, was arranged in a tissue microarray (ethical approval no.
59CI8ABR2002) and analyzed by HIF-2a and VEGF immunohistochemistry.
Median age at diagnosis was 19 months, follow-up data were available for
79 patients, and follow-up time ranged between 1 and 88 months (S.N.,
R.N., E.F., and S.P., unpublished data). Forty samples wereMYCN amplified,
53 were 1p36 deleted, and distribution in clinical stages (INSS) was as fol-
lows: stage 1 (19), stage 2 (5), stage 3 (13), stage 4 (39), stage 4s (7), and un-
classified (10). High-stage, MYCN-amplified, and 1p36-deleted tumors were
slightly overrepresented compared to a population-based distribution. Es-
tablished prognostic markers, e.g., clinical stage, MYCN amplification, and
1p36 deletion were all prognostically highly significant in this material (data
not shown). Immunoreactivity was independently scored by two pathologists
and classified according to range, i.e., fractions of positive cells (0, 0%–10%;
1, 10%–25%; 2, 26%–75%; 3, 76%–100%) and general intensity of positive
cells (0, none; 1, mild; 2, moderate; 3, intense). For survival analysis and
correlation to stage, groups 0 and 1 (low) and 2 and 3 (high) were pooled,
respectively. All statistical calculations were performed using SPSS 12.0.1
(SPSS Inc.).
Microarray analysis
mRNA from SK-N-BE(2)c cells grown at 1%, 5%, or 21% O2 were hybridized
to microarrays (w27,000 unique clones) produced at the Swegene DNA Mi-
croarray Resource Center, Lund University. Genes with a specific response
pattern were identified using a vector projection method onto a given trend of
interest. Data analyses and statistical computations were performed using
BASE (Saal et al., 2002), Perl (http://www.perl.org/), and R (http://www.
r-project.org/). Identification of unknown array reporters was done using
TFASTA. See the Supplemental Experimental Procedures for a detailed de-
scription of microarray platform and analyses.
ChIP assay
Cells were cultured at 21% O2 or reduced oxygen, and ChIP analyses were
performed as previously described (Lo¨fstedt et al., 2004), using antibodies
against HIF-1a (Santa Cruz), HIF-2a (Novus), or IgG (Abcam). PCR primers
flanking the HREs of the VEGF and DEC1/BHLHB2 promoters are given in
Table S1.
Transfection, luciferase assay, and siRNA
Triplicates of 83 104 SK-N-BE(2)c cells in 24-well culture plates were trans-
fected with 300 ng of a vector containing three copies of the erythropoietin
(EPO) HRE in tandem, coupled to a Luciferase reporter gene (Kallio et al.,
1999; Lo¨fstedt et al., 2004). As a control of transfection efficiency, 50 ng of
a CMV Renilla Luciferase vector (Promega) was included. Transfections
were performed with Lipofectamine-2000 for 6 hr in OptiMEM I Reduced Se-
rum Medium (Invitrogen), and cells were harvested after 24 hr of culture at in-
dicated oxygen levels. The luciferase activity was measured and calculated
using the Dual-Luciferase Reporter Assay System (Promega). In a set of421
A R T I C L Eexperiments, cells were transfected with siRNA duplexes (Ambion) against
HIF-1a and HIF-2a, respectively, at a final concentration of 50 nM. As control
siRNAs, the inverted or a scrambled HIF-1a sequence were used. Sense and
antisense siRNA sequences are given in Table S1 and have been previously
described (Sowter et al., 2003).
Xenograft tumor model
SK-N-BE(2)c cells were transiently transfected with HIF-2a, HIF-1a, or
scrambled (control) siRNA. Cells were injected subcutaneously (5 3 106
cells/200 ml PBS/mouse) on the back of athymic mice (NMRI strain nu/nu).
Six- to eight-week-old female mice weighing 20–25 g at arrival were used
and housed in a controlled environment. All procedures were approved by
the regional ethical committee for animal research (approval no. M66-05).
Tumor growth was monitored on a daily basis, and volume was calculated
as pls2/6, where l = long side and s = short side.
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures,
three supplemental figures, and one supplemental table and can be found
with this article online at http://www.cancercell.org/cgi/content/full/10/5/
413/DC1/.
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